Completed PHASE4 INTERVENTIONAL 1-arm NCT06176651

Evaluation of Miebo (Perfluorohexyloctane) Eyedrops in Habitual Contact Lens Wearers

Sponsor: Gordon Schanzlin New Vision

Conditions Dry Eye Dry Eye Disease Dry Eye, Evaporative Evaporative Dry Eye Evaporative Dry Eye Disease Kerato Conjunctivitis Sicca

Interventions Miebo

Updated 4 times since 2024 Last updated: Apr 5, 2024 Started: Sep 21, 2023 Primary completion: Apr 5, 2024 Completion: Apr 5, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06176651, this PHASE4 trial focuses on Dry Eye and Dry Eye Disease and remains completed. Sponsored by Gordon Schanzlin New Vision, it has been updated 4 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
May 2024 — Jul 2024 [monthly]

Completed PHASE4

Status: Recruiting → Completed
Jan 2024 — May 2024 [monthly]

Recruiting PHASE4

First recorded

Sep 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Gordon Schanzlin New Vision

Data source: Gordon Schanzlin New Vision

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• San Diego, United States